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611 ERCPs 
Reviewed
284 ERCPs for 
Suspected CDL



























Retrospective Study Assessing Rate of False Positive Endoscopic Retrograde 






• Age > 18
• Negative ERCP for CDL
• Exclusion Criteria:
• ERCP performed not for CDL
• Positive ERCP for CDL





• CDL risk based on Table 1
Retrospective 
Chart Review
• Determine if post-ERCP pancreatitis
developed
• Record lipase level, symptoms and
imaging of post-ERCP pancreatitis
Analyze data
• Incidence of negative ERCP for CDL
• Incidence of post-ERCP pancreatitis
for entire sample
• Incidence of post-ERCP pancreatitis
based on CDL risk
Table 1: Risk Criteria Classification
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Pre-ERCP Data Post-ERCP Data
Patient 
Age








Nausea Vomiting Imaging 
Confirming 
Pancreatitis
69 Low No MRCP, 
IOC
1071 Yes Yes Yes Not 
Performed
27 Intermediate Yes EUS 22746 Yes No No Not 
Performed
62 Low No IOC 8911 No Yes No Not 
Performed
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Problem Statement
• Choledocholithiasis (CDL) refers to the presence of
gallstones within the common bile duct (CBD).
• CDL is diagnosed and treated by endoscopic
retrograde cholangiopancreatography (ERCP).
• ERCP is an invasive procedure that cannulates and
retrieves gallstones in the CBD.
• 5-10% of patients who undergo ERCP develop post-
ERCP pancreatitis.
• With minimal risks, EUS can be used to pre-screen
patients for CDL.
• Pre-screening may decrease unnecessary ERCPs
and thus decrease post-ERCP pancreatitis.
A retrospective study has yet to be performed at LVHN to 
determine the rate of false positive ERCPs and their 
associated complications and thus no data exists to 
analyze if additional pre-screening prior to an ERCP 
would be beneficial in patients suspected of CDL.
92%
8%





Figure 1: Study Flowchart of Chart Review
Figure 3: Number of Patients in Each CDL Risk 
Category
Table 2: Sub-Analysis of Patients Who Developed 
Post-ERCP Pancreatitis
Conclusions
• 39 patients (14%) had negative ERCPs, in which 3
patients (7.7%), who were low/intermediate CDL risk,
developed post-ERCP pancreatitis.
• Length of stay (LOS) prolonged in 2 of the 3 patients
(67%) who developed pancreatitis when compared to
the mean LOS of 5.3 days of all patients with negative
ERCPs (power 0.2).
• Extended LOS on average for post-ERCP
complications is ~$6,000 for additional 2-3 days of
hospitalization.
• No high risk patients developed post-ERCP
pancreatitis.
• No significant difference (p>0.5) in patient
characteristics or test results between patients who
developed pancreatitis and those who did not.
Project Limitations:
1. Small sample size, resulting in low power.
1. 26 patient charts excluded due to ERCP being
cancelled after EUS pre-screening ruled out CDL.
• Pre-screening with EUS for patients with low and
intermediate CDL risk would provide cost-effective
benefit by avoiding unnecessary ERCPs that may
cause costly complications.
• Why EUS?
1. High sensitivity (93-97%) & specificity (89-94%)
1. Ability to be performed immediately prior to
ERCP, limiting time for gallstone to pass between
screening and ERCP
2. Cost of EUS with ERCP comparable to cost of
ERCP alone
• More data needed to determine if pre-screening would
be beneficial for patients at high risk of CDL.
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